Insider Buying: Avalo Therapeutics Inc (NASDAQ:AVTX) Director Purchases 85,000 Shares of Stock

Avalo Therapeutics Inc (NASDAQ:AVTX) Director Armistice Capital, Llc bought 85,000 shares of the stock in a transaction dated Friday, January 14th. The shares were acquired at an average cost of $0.93 per share, for a total transaction of $79,050.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Armistice Capital, Llc also recently made the following trade(s):

  • On Wednesday, January 12th, Armistice Capital, Llc purchased 57,300 shares of Avalo Therapeutics stock. The shares were purchased at an average price of $1.04 per share, for a total transaction of $59,592.00.
  • On Monday, January 10th, Armistice Capital, Llc purchased 491,097 shares of Avalo Therapeutics stock. The shares were purchased at an average price of $0.99 per share, for a total transaction of $486,186.03.
  • On Friday, January 7th, Armistice Capital, Llc purchased 137,900 shares of Avalo Therapeutics stock. The shares were purchased at an average price of $1.04 per share, for a total transaction of $143,416.00.

Shares of Avalo Therapeutics stock opened at $1.00 on Friday. Avalo Therapeutics Inc has a fifty-two week low of $0.90 and a fifty-two week high of $4.50. The company has a current ratio of 4.04, a quick ratio of 4.04 and a debt-to-equity ratio of 0.81. The company has a 50 day moving average of $1.86.

Avalo Therapeutics (NASDAQ:AVTX) last issued its earnings results on Tuesday, November 9th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.01. Avalo Therapeutics had a negative net margin of 1,211.01% and a negative return on equity of 272.08%. The firm had revenue of $1.35 million for the quarter. Equities analysts anticipate that Avalo Therapeutics Inc will post -0.84 EPS for the current fiscal year.

Several research firms recently issued reports on AVTX. Oppenheimer reiterated a “buy” rating and set a $5.00 price target on shares of Avalo Therapeutics in a research report on Friday, January 7th. Zacks Investment Research lowered shares of Avalo Therapeutics from a “buy” rating to a “sell” rating in a research report on Tuesday. Finally, Royal Bank of Canada initiated coverage on shares of Avalo Therapeutics in a research report on Friday, September 24th. They set an “outperform” rating and a $6.00 price target on the stock.

Large investors have recently modified their holdings of the company. Caas Capital Management LP acquired a new position in shares of Avalo Therapeutics during the third quarter worth $26,000. Cambridge Investment Research Advisors Inc. acquired a new position in shares of Avalo Therapeutics during the third quarter worth $27,000. Creative Planning acquired a new position in shares of Avalo Therapeutics during the third quarter worth $32,000. Victory Capital Management Inc. acquired a new position in shares of Avalo Therapeutics during the third quarter worth $34,000. Finally, SG Americas Securities LLC acquired a new position in shares of Avalo Therapeutics during the third quarter worth $41,000. Institutional investors own 75.60% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics, Inc is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation.

Featured Article: How does equity income fit into an investing strategy?

Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.